The latest Special Issue of The FEBS Journal, introduced by Inna Afonina and Eik Hoffmann, consists of 20 reviews covering various aspects and new developments in ‘Infection and Immunity’.

The issue includes expert views on the role of different immune cell populations, on the regulation of innate and adaptive immune responses, and novel concepts in host defence and inflammatory signalling. Many reviews in this issue also highlight potential targets for future therapeutic interventions that aim to tackle inflammatory and immune responses in health and disease.

We hope you enjoy reading our latest special issue found here: Infection and Immunity: The FEBS Journal: Vol 289, No 14 (wiley.com) 

References

• 1 Afonina IS, Hoffmann E. Infection and immunity: 'There Are Things Out There You (Don't) Need To Know About'. FEBS J. 2022; 289: 3920-25
• 2 The FEBS Journal Editorial Team, Beyaert R. Editor Profile: Rudi Beyaert. FEBS J. 2022; 289: 3926– 31.
• 3 Othman A, Sekheri M, Filep JG. Roles of neutrophil granule proteins in orchestrating inflammation and immunity. FEBS J. 2022; 289: 3932– 53.
• 4 Liu ML, Lyu X, Werth WP. Recent progress in the mechanistic understanding of NET formation in neutrophils. FEBS J. 2022; 289: 3954– 66.
• 5 Bennstein SB, Uhrberg M. Biology and therapeutic potential of human innate lymphoid cells. FEBS J. 2022; 289: 3967– 81.
• 6 Piersma SJ, Brizić I. Natural killer cell effector functions in antiviral defense. FEBS J. 2022; 289: 3982– 99.
• 7 Zhuo X, Wu Y, Fu X, Liang X, Xiang Y, Li J, et al. The Yin-Yang roles of protease-activated receptors in inflammatory signalling and diseases. FEBS J. 2022; 289: 4000– 20.
• 8 Bauer KM, Round JL, O'Connell RM. No small matter: emerging roles for exosomal miRNAs in the immune system. FEBS J. 2022; 289: 4021– 37.
• 9 Froggatt HM, Heaton NS. Nonrespiratory sites of influenza-associated disease: mechanisms and experimental systems for continued study. FEBS J. 2022; 289: 4038– 60.
• 10 Mia MM, Singh MK. Emerging roles of the Hippo signaling pathway in modulating immune response and inflammation-driven tissue repair and remodelling. FEBS J. 2022; 289: 4061– 81.
• 11 Huoh YS, Hur S. Death domain fold proteins in immune signaling and transcriptional regulation. FEBS J. 2022; 289: 4082– 97.
• 12 Fang Y, Peng K. Regulation of innate immune responses by cell death-associated caspases during virus infection. FEBS J. 2022; 289: 4098– 111.
• 13 Chauhan S, Jena KK, Mehto S, Chauhan NR, Sahu R, Dhar K, et al. Innate immunity and inflammophagy: balancing the defence and immune homeostasis. FEBS J. 2022; 289: 4112– 31.
• 14 Maruyama K. Senso-immunology: crosstalk between nociceptive and immune systems. FEBS J. 2022; 289: 4132– 45.
• 15 Pal R, Bisht MK, Mukhopadhyay S. Secretory proteins of Mycobacterium tuberculosis and their roles in modulation of host immune responses: focus on therapeutic targets. FEBS J. 2022; 289: 4146– 71.
• 16 Fatima S, Kumari A, Agarwal M, Pahuja I, Yadav V, Dwivedi VP, et al. Epigenetic code during mycobacterial infections: therapeutic implications for tuberculosis. FEBS J. 2022; 289: 4172– 91.
• 17 Sibinelli-Sousa S, de Araújo-Silva AL, Hespanhol JT, Bayer-Santos E. Revisiting the steps of Salmonella gut infection with a focus on antagonistic interbacterial interactions. FEBS J. 2022; 289: 4192– 211.
• 18 Jordan PM, Werz O. Specialized pro-resolving mediators: biosynthesis and biological role in bacterial infections. FEBS J. 2022; 289: 4212– 27.
• 19 Aaron TS, Fooksman DR. Dynamic organization of the bone marrow plasma cell niche. FEBS J. 2022; 289: 4228– 39.
• 20 Quaglia F, Salladini E, Carraro M, Minervini G, Tosatto SCE, Le Mercier P. SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion. FEBS J. 2022; 289: 4240– 50.
• 21 Anderluh M, Berti F, Bzducha-Wróbel A, Chiodo F, Colombo C, Compostella F, et al. Recent advances on smart glycoconjugate vaccines in infections and cancer. FEBS J. 2022; 289: 4251– 303.
• 22 Rossotti MA, Bélanger K, Henry KA, Tanha J. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022; 289: 4304– 27.